Sign In

Login

Password

Forgot Password ? Sign Up

Amfetamina (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Amfetamina" in Polish language version.

refsWebsite
Global rank Polish rank
135nih.gov
4th place
7th place
116doi.org
2nd place
6th place
19fda.gov
447th place
1,118th place
17web.archive.org
1st place
1st place
5books.google.com
3rd place
27th place
4drugbank.ca
4,294th place
205th place
3worldcat.org
5th place
2nd place
3brenda-enzymes.info
low place
low place
3unodc.org
2,494th place
2,839th place
2europa.eu
68th place
31st place
2merckmanuals.com
3,097th place
low place
2genome.jp
low place
low place
2espacenet.com
800th place
2,486th place
1sigmaaldrich.com
924th place
75th place
1who.int
195th place
256th place
1un.org
97th place
142nd place
1evekeo.com
low place
low place
1mhmedical.com
6,846th place
low place
1acha.org
low place
low place
1webmd.com
1,169th place
2,752nd place
1jsonline.com
1,392nd place
low place
1ncaapublications.com
7,706th place
low place
1wiley.com
222nd place
228th place
1inchem.org
4,334th place
2,789th place
1trispharma.com
low place
low place
1jiaci.org
low place
low place
1guidetopharmacology.org
low place
low place
1t3db.ca
low place
low place
1univ-paris5.fr
low place
2,637th place
1jbc.org
4,455th place
6,144th place
1healthvermont.gov
low place
low place
1nwafs.org
low place
low place
1wordsareimportant.com
low place
low place
1internetjournalofcriminology.com
low place
low place
1untruth.org
low place
low place
1incb.org
low place
4,776th place
1koreatimes.co.kr
536th place
1,541st place
1mhlw.go.jp
1,656th place
low place
1justice.gc.ca
2,540th place
low place
1overheid.nl
3,288th place
5,829th place
1comlaw.gov.au
low place
low place
1moph.go.th
low place
low place
1homeoffice.gov.uk
low place
low place

acha.org

books.google.com

brenda-enzymes.info

comlaw.gov.au

doi.org

doi.org

  • Liddle DG, Connor DJ. Nutritional supplements and ergogenic AIDS. „Prim. Care”. 40 (2), s. 487–505, June 2013. DOI: 10.1016/j.pop.2013.02.009. PMID: 23668655. 
  • Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929–1950. „J. Hist. Med. Allied Sci.”. 61 (3), s. 288–323, 2006. DOI: 10.1093/jhmas/jrj039. PMID: 16492800. 
  • Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. „J. Am. Acad. Child Adolesc. Psychiatry”. 47 (1), s. 21–31, 2008. DOI: 10.1097/chi.0b013e31815a56f1. PMID: 18174822. 
  • Grandy DK, Miller GM, Li JX. „TAARgeting Addiction”-The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference. „Drug Alcohol Depend.”. 159, s. 9–16, 2016. DOI: 10.1016/j.drugalcdep.2015.11.014. PMID: 26644139. 
  • Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. „Curr. Med. Res. Opin.”. 24 (5), s. 1345–1357, 2008. DOI: 10.1185/030079908X280707. PMID: 18384709. 
  • Broadley KJ. The vascular effects of trace amines and amphetamines. „Pharmacol. Ther.”. 125 (3), s. 363–375, March 2010. DOI: 10.1016/j.pharmthera.2009.11.005. PMID: 19948186. 
  • Hagel JM, Krizevski R, Marsolais F, Lewinsohn E, Facchini PJ. Biosynthesis of amphetamine analogs in plants. „Trends Plant Sci.”. 17 (7), s. 404–412, 2012. DOI: 10.1016/j.tplants.2012.03.004. PMID: 22502775. 
  • Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L. Toxicity of amphetamines: an update. „Arch. Toxicol.”. 86 (8), s. 1167–1231, August 2012. DOI: 10.1007/s00204-012-0815-5. PMID: 22392347. 
  • Scholten RJ, Clarke M, Hetherington J. The Cochrane Collaboration. „Eur. J. Clin. Nutr.”. 59 Suppl 1, s. S147–S149; dyskusja S195–S196, 2005. DOI: 10.1038/sj.ejcn.1602188. PMID: 16052183. 
  • Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. „Cochrane Database Syst. Rev.”, s. CD007813, 2011. DOI: 10.1002/14651858.CD007813.pub2. PMID: 21678370. 
  • Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, Vohra S. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. „Cochrane Database Syst. Rev.”. 2, s. CD009996, 2016. DOI: 10.1002/14651858.CD009996.pub2. PMID: 26844979. 
  • Pringsheim T, Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. „Cochrane Database Syst. Rev.”, s. CD007990, 2011. DOI: 10.1002/14651858.CD007990.pub2. PMID: 21491404. 
  • Spencer RC, Devilbiss DM, Berridge CW. The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex. „Biol. Psychiatry”. 77 (11), s. 940–950, June 2015. DOI: 10.1016/j.biopsych.2014.09.013. PMID: 25499957. 
  • Ilieva IP, Hook CJ, Farah MJ. Prescription Stimulants’ Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis. „J. Cogn. Neurosci.”, s. 1–21, 2015. DOI: 10.1162/jocn_a_00776. PMID: 25591060. 
  • Wood S, Sage JR, Shuman T, Anagnostaras SG. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. „Pharmacol. Rev.”. 66 (1), s. 193–221, January 2014. DOI: 10.1124/pr.112.007054. PMID: 24344115. 
  • Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. „Postgrad. Med.”. 126 (5), s. 64–81, 2014. DOI: 10.3810/pgm.2014.09.2801. PMID: 25295651. 
  • Parr JW. Attention-deficit hyperactivity disorder and the athlete: new advances and understanding. „Clin. Sports Med.”. 30 (3), s. 591–610, July 2011. DOI: 10.1016/j.csm.2011.03.007. PMID: 21658550. 
  • Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R. Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing. „Sports Med.”. 43 (5), s. 301–311, May 2013. DOI: 10.1007/s40279-013-0030-4. PMID: 23456493. 
  • Rattray B, Argus C, Martin K, Northey J, Driller M. Is it time to turn our attention toward central mechanisms for post-exertional recovery strategies and performance?. „Front. Physiol.”. 6, s. 79, 2015. DOI: 10.3389/fphys.2015.00079. PMID: 25852568. PMCID: PMC4362407. 
  • Roelands B, De Pauw K, Meeusen R. Neurophysiological effects of exercise in the heat. „Scand. J. Med. Sci. Sports”. 25 Suppl 1, s. 65–78, 2015. DOI: 10.1111/sms.12350. PMID: 25943657. [dostęp 2016-03-10]. 
  • Kessler S. Drug therapy in attention-deficit hyperactivity disorder. „South. Med. J.”. 89 (1), s. 33–38, 1996. DOI: 10.1097/00007611-199601000-00005. PMID: 8545689. 
  • Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. „J. Clin. Psychiatry”. 65 (11), s. 1520–1524, 2004. DOI: 10.4088/jcp.v65n1113. PMID: 15554766. 
  • Stewart JW, Deliyannides DA, McGrath PJ. How treatable is refractory depression?. „J. Affect. Disord.”. 167, s. 148–152, 2014. DOI: 10.1016/j.jad.2014.05.047. PMID: 24972362. 
  • Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O’Duffy A, Connell FA, Ray WA. ADHD drugs and serious cardiovascular events in children and young adults. „N. Engl. J. Med.”. 365 (20), s. 1896–1904, 2011. DOI: 10.1056/NEJMoa1110212. PMID: 22043968. 
  • Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. „JAMA”. 306 (24), s. 2673–2683, 2011. DOI: 10.1001/jama.2011.1830. PMID: 22161946. PMCID: PMC3350308. 
  • Spiller HA, Hays HL, Aleguas A. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. „CNS Drugs”. 27 (7), s. 531–543, June 2013. DOI: 10.1007/s40263-013-0084-8. PMID: 23757186. 
  • Ruffle JK. Molecular neurobiology of addiction: what’s all the (Δ)FosB about?. „Am. J. Drug Alcohol Abuse”. 40 (6), s. 428–437, 2014. DOI: 10.3109/00952990.2014.933840. PMID: 25083822. 
  • Zhou Y, Zhao M, Zhou C, Li R. Sex differences in drug addiction and response to exercise intervention: From human to animal studies. „Front. Neuroendocrinol.”, 2015. DOI: 10.1016/j.yfrne.2015.07.001. PMID: 26182835. 
  • Linke SE, Ussher M. Exercise-based treatments for substance use disorders: evidence, theory, and practicality. „Am. J. Drug Alcohol Abuse”. 41 (1), s. 7–15, 2015. DOI: 10.3109/00952990.2014.976708. PMID: 25397661. 
  • Perez-Mana C, Castells X, Torrens M, Capella D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. „Cochrane Database Syst. Rev.”. 9, s. CD009695, 2013. DOI: 10.1002/14651858.CD009695.pub2. PMID: 23996457. 
  • Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. „Annu. Rev. Neurosci.”. 29, s. 565–598, July 2006. DOI: 10.1146/annurev.neuro.29.051605.113009. PMID: 16776597. 
  • Beloate LN, Weems PW, Casey GR, Webb IC, Coolen LM. Nucleus accumbens NMDA receptor activation regulates amphetamine cross-sensitization and deltaFosB expression following sexual experience in male rats. „Neuropharmacology”. 101, s. 154–164, 2016. DOI: 10.1016/j.neuropharm.2015.09.023. PMID: 26391065. 
  • Stoops WW, Rush CR. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. „Expert Rev Clin Pharmacol”. 7 (3), s. 363–374, 2014. DOI: 10.1586/17512433.2014.909283. PMID: 24716825. 
  • Jing L, Li JX. Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction. „Eur. J. Pharmacol.”. 761, s. 345–352, 2015. DOI: 10.1016/j.ejphar.2015.06.019. PMID: 26092759. 
  • Advokat C. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. „J. Atten. Disord.”. 11 (1), s. 8–16, 2007. DOI: 10.1177/1087054706295605. PMID: 17606768. 
  • Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. „Neurotox. Res.”. 1 (3), s. 181–195, February 2000. DOI: 10.1007/BF03033289. PMID: 12835101. 
  • Krause J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. „Expert Rev. Neurother.”. 8 (4), s. 611–625, 2008. DOI: 10.1586/14737175.8.4.611. PMID: 18416663. 
  • Scholze P, Nørregaard L, Singer EA, Freissmuth M, Gether U, Sitte HH. The role of zinc ions in reverse transport mediated by monoamine transporters. „J. Biol. Chem.”. 277 (24), s. 21505–21513, 2002. DOI: 10.1074/jbc.M112265200. PMID: 11940571. 
  • Scassellati C, Bonvicini C, Faraone SV, Gennarelli M. Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. „J. Am. Acad. Child Adolesc. Psychiatry”. 51 (10), s. 1003–1019.e20, 2012. DOI: 10.1016/j.jaac.2012.08.015. PMID: 23021477. 
  • Rytting E, Audus KL. Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. „J. Pharmacol. Exp. Ther.”. 312 (1), s. 192–198, January 2005. DOI: 10.1124/jpet.104.072363. PMID: 15316089. 
  • Vicentic A, Jones DC. The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction. „J. Pharmacol. Exp. Ther.”. 320 (2), s. 499–506, February 2007. DOI: 10.1124/jpet.105.091512. PMID: 16840648. 
  • Zhang M, Han L, Xu Y. Roles of cocaine- and amphetamine-regulated transcript in the central nervous system. „Clin. Exp. Pharmacol. Physiol.”. 39 (6), s. 586–592, June 2012. DOI: 10.1111/j.1440-1681.2011.05642.x. PMID: 22077697. 
  • Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA. Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. „Biol. Psychiatry”. 72 (5), s. 371–377, 2012. DOI: 10.1016/j.biopsych.2012.01.027. PMID: 22386378. 
  • Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L, Brasic J, Wand GS. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. „Neuropsychopharmacology”. 30 (4), s. 821–832, 2005. DOI: 10.1038/sj.npp.1300667. PMID: 15702139. 
  • Horwitz D, Alexander RW, Lovenberg W, Keiser HR. Human serum dopamine-β-hydroxylase. Relationship to hypertension and sympathetic activity. „Circ. Res.”. 32 (5), s. 594–599, 1973. DOI: 10.1161/01.RES.32.5.594. PMID: 4713201. 
  • Santagati NA, Ferrara G, Marrazzo A, Ronsisvalle G. Simultaneous determination of amphetamine and one of its metabolites by HPLC with electrochemical detection. „J. Pharm. Biomed. Anal.”. 30 (2), s. 247–255, September 2002. DOI: 10.1016/S0731-7085(02)00330-8. PMID: 12191709. 
  • Lindemann L, Hoener MC. A renaissance in trace amines inspired by a novel GPCR family. „Trends Pharmacol. Sci.”. 26 (5), s. 274–281, May 2005. DOI: 10.1016/j.tips.2005.03.007. PMID: 15860375. 
  • Brussee J, Jansen AC. A highly stereoselective synthesis of s(–)-[1,1'-binaphthalene]-2,2'-diol. „Tetrahedron Lett.”. 24 (31), s. 3261–3262, 1983. DOI: 10.1016/S0040-4039(00)88151-4. 
  • Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. „Clin. Toxicol. (Phila.)”. 48 (7), s. 675–694, August 2010. DOI: 10.3109/15563650.2010.516752. ISSN 1556-3650. PMID: 20849327. 
  • Lillsunde P, Korte T. Determination of ring- and N-substituted amphetamines as heptafluorobutyryl derivatives. „Forensic Sci. Int.”. 49 (2), s. 205–213, 1991. DOI: 10.1016/0379-0738(91)90081-s. PMID: 1855720. 
  • Allen A, Cantrell TS. Synthetic reductions in clandestine amphetamine and methamphetamine laboratories: A review. „Forensic Science International”. 42 (3), s. 183–199, 1989. DOI: 10.1016/0379-0738(89)90086-8. 
  • Pollard CB, Young DC. The Mechanism of the Leuckart Reaction. „J. Org. Chem.”. 16 (5), s. 661–672, May 1951. DOI: 10.1021/jo01145a001. 
  • Patrick TM, McBee ET, Hass HB. Synthesis of arylpropylamines; from allyl chloride. „J. Am. Chem. Soc.”. 68, s. 1009–1011, 1946. DOI: 10.1021/ja01210a032. PMID: 20985610. 
  • Ritter JJ, Kalish J. A new reaction of nitriles; synthesis of t-carbinamines. „J. Am. Chem. Soc.”. 70 (12), s. 4048–4050, 1948. DOI: 10.1021/ja01192a023. PMID: 18105933. 
  • Krimen LI, Cota DJ. The Ritter Reaction. „Organic Reactions”. 17, s. 216, 2011. DOI: 10.1002/0471264180.or017.03. 
  • Collins M, Salouros H, Cawley AT, Robertson J, Heagney AC, Arenas-Queralt A. δ13C and δ2H isotope ratios in amphetamine synthesized from benzaldehyde and nitroethane. „Rapid Commun. Mass Spectrom.”. 24 (11), s. 1653–1658, June 2010. DOI: 10.1002/rcm.4563. PMID: 20486262. 
  • Kraemer T, Maurer HH. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. „J. Chromatogr. B Biomed. Sci. Appl.”. 713 (1), s. 163–187, August 1998. DOI: 10.1016/S0378-4347(97)00515-X. PMID: 9700558. 
  • Kraemer T, Paul LD. Bioanalytical procedures for determination of drugs of abuse in blood. „Anal. Bioanal. Chem.”. 388 (7), s. 1415–1435, August 2007. DOI: 10.1007/s00216-007-1271-6. PMID: 17468860. 
  • Goldberger BA, Cone EJ. Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry. „J. Chromatogr. A.”. 674 (1–2), s. 73–86, 1994. DOI: 10.1016/0021-9673(94)85218-9. PMID: 8075776. 
  • Paul BD, Jemionek J, Lesser D, Jacobs A, Searles DA. Enantiomeric separation and quantitation of (±)-amphetamine (±)-methamphetamine (±)-MDA (±)-MDMA, and (±)-MDEA in urine specimens by GC-EI-MS after derivatization with (R)-(–)- or (S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (MTPA). „J. Anal. Toxicol.”. 28 (6), s. 449–455, September 2004. DOI: 10.1093/jat/28.6.449. PMID: 15516295. 
  • Verstraete AG, Heyden FV. Comparison of the sensitivity and specificity of six immunoassays for the detection of amphetamines in urine. „J. Anal. Toxicol.”. 29 (5), s. 359–364, 2005. DOI: 10.1093/jat/29.5.359. PMID: 16105261. 
  • Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. „Drug Metab. Rev.”. 32 (1), s. 15–44, February 2000. DOI: 10.1081/DMR-100100562. PMID: 10711406. 
  • Cody JT. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. „J. Occup. Environ. Med.”. 44 (5), s. 435–450, May 2002. DOI: 10.1097/00043764-200205000-00012. PMID: 12024689. 
  • Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. „Prog. Neurobiol.”. 75 (6), s. 406–433, 2005. DOI: 10.1016/j.pneurobio.2005.04.003. PMID: 15955613. 
  • Rasmussen N. Medical science and the military: the Allies’ use of amphetamine during World War II. „J. Interdiscip. Hist.”. 42 (2), s. 205–233, August 2011. DOI: 10.1162/JINH_a_00212. PMID: 22073434. 
  • Defalque RJ, Wright AJ. Methamphetamine for Hitler’s Germany: 1937 to 1945. „Bull. Anesth. Hist.”. 29 (2), s. 21–24, 32, April 2011. DOI: 10.1016/s1522-8649(11)50016-2. PMID: 22849208. 

dx.doi.org

drugbank.ca

  • Amphetamine. [w:] DrugBank [on-line]. University of Alberta, 8 February 2013. [dostęp 2013-10-13].
  • Dextroamphetamine, [w:] DrugBank [online], University of Alberta, 8 lutego 2013 [dostęp 2013-11-05].
  • Amphetamine. [w:] DrugBank [on-line]. University of Alberta, 2013-02-08. [dostęp 2013-11-05].
  • Lisdexamfetamine. [w:] Drugbank [on-line]. University of Alberta, 2013-02-08. [dostęp 2013-10-13].

espacenet.com

worldwide.espacenet.com

europa.eu

emcdda.europa.eu

evekeo.com

fda.gov

accessdata.fda.gov

fda.gov

genome.jp

guidetopharmacology.org

healthvermont.gov

homeoffice.gov.uk

incb.org

inchem.org

  • Heedes G, Ailakis J: Amphetamine (PIM 934). International Programme on Chemical Safety. [dostęp 2014-06-24].

internetjournalofcriminology.com

jbc.org

jiaci.org

jsonline.com

justice.gc.ca

laws-lois.justice.gc.ca

koreatimes.co.kr

merckmanuals.com

  • O’Connor PG: Amphetamines. [w:] Merck Manual for Health Care Professionals [on-line]. Merck, February 2012. [dostęp 2012-05-08].
  • Amphetamines: Drug Use and Abuse. [w:] Merck Manual Home Edition [on-line]. Merck, February 2003. [dostęp 2007-02-28]. [zarchiwizowane z tego adresu (17 February 2007)].

mhlw.go.jp

mhmedical.com

accessmedicine.mhmedical.com

moph.go.th

narcotic.fda.moph.go.th

ncaapublications.com

nih.gov

ncbi.nlm.nih.gov

  • Shaun L. Greene, Fergus Kerr, George Braitberg, Review article: amphetamines and related drugs of abuse, „Emergency Medicine Australasia”, 20 (5), 2008, s. 391–402, DOI: 10.1111/j.1742-6723.2008.01114.x, PMID: 18973636.
  • D.J. Heal i inni, Amphetamine, past and present – a pharmacological and clinical perspective, „Journal of Psychopharmacology”, 27 (6), 2013, s. 479–496, DOI: 10.1177/0269881113482532, PMID: 23539642, PMCID: PMC3666194.
  • Liddle DG, Connor DJ. Nutritional supplements and ergogenic AIDS. „Prim. Care”. 40 (2), s. 487–505, June 2013. DOI: 10.1016/j.pop.2013.02.009. PMID: 23668655. 
  • Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929–1950. „J. Hist. Med. Allied Sci.”. 61 (3), s. 288–323, 2006. DOI: 10.1093/jhmas/jrj039. PMID: 16492800. 
  • Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. „J. Am. Acad. Child Adolesc. Psychiatry”. 47 (1), s. 21–31, 2008. DOI: 10.1097/chi.0b013e31815a56f1. PMID: 18174822. 
  • K.A. Montgomery, Sexual desire disorders, „Psychiatry”, 5 (6), 2008, s. 50–55, PMID: 19727285, PMCID: PMC2695750.
  • G.M. Miller, The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity, „Journal of Neurochemistry”, 116 (2), 2011, s. 164–176, DOI: 10.1111/j.1471-4159.2010.07109.x, PMID: 21073468, PMCID: PMC3005101.
  • Grandy DK, Miller GM, Li JX. „TAARgeting Addiction”-The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference. „Drug Alcohol Depend.”. 159, s. 9–16, 2016. DOI: 10.1016/j.drugalcdep.2015.11.014. PMID: 26644139. 
  • Shoptaw SJ, Kao U, Ling W, Treatment for amphetamine psychosis, Shoptaw SJ, Ali R (red.), „Cochrane Database of Systematic Reviews” (1), 2009, DOI: 10.1002/14651858.CD003026.pub3, PMID: 19160215, CD003026.
  • Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. „Curr. Med. Res. Opin.”. 24 (5), s. 1345–1357, 2008. DOI: 10.1185/030079908X280707. PMID: 18384709. 
  • Broadley KJ. The vascular effects of trace amines and amphetamines. „Pharmacol. Ther.”. 125 (3), s. 363–375, March 2010. DOI: 10.1016/j.pharmthera.2009.11.005. PMID: 19948186. 
  • Hagel JM, Krizevski R, Marsolais F, Lewinsohn E, Facchini PJ. Biosynthesis of amphetamine analogs in plants. „Trends Plant Sci.”. 17 (7), s. 404–412, 2012. DOI: 10.1016/j.tplants.2012.03.004. PMID: 22502775. 
  • Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L. Toxicity of amphetamines: an update. „Arch. Toxicol.”. 86 (8), s. 1167–1231, August 2012. DOI: 10.1007/s00204-012-0815-5. PMID: 22392347. 
  • Berman S i inni, Abuse of amphetamines and structural abnormalities in the brain, „Annals of the New York Academy of Sciences”, 1141, 2008, s. 195–220, DOI: 10.1196/annals.1441.031, PMID: 18991959, PMCID: PMC2769923.
  • H. Hart i inni, Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects, „JAMA Psychiatry”, 70 (2), 2013, s. 185–198, DOI: 10.1001/jamapsychiatry.2013.277, PMID: 23247506.
  • T.J. Spencer i inni, Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies, „The Journal of Clinical Psychiatry”, 74 (9), 2013, s. 902–917, DOI: 10.4088/JCP.12r08287, PMID: 24107764, PMCID: PMC3801446.
  • T. Frodl, N. Skokauskas, Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects, „Acta Psychiatrica Scandinavica”, 125 (2), 2012, s. 114–126, DOI: 10.1111/j.1600-0447.2011.01786.x, PMID: 22118249.
  • L.E. Arnold i inni, Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review, „PLoS ONE”, 10 (2), 2015, e0116407, DOI: 10.1371/journal.pone.0116407, PMID: 25714373, PMCID: PMC4340791.
    Figure 3: Treatment benefit by treatment type and outcome group.
  • Yu-Shu Huang, Ming-Horng Tsai, Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge, „CNS drugs”, 25 (7), 2011, s. 539–554, DOI: 10.2165/11589380-000000000-00000, PMID: 21699268.
  • Bidwell LC, McClernon FJ, Kollins SH, Cognitive enhancers for the treatment of ADHD, „Pharmacol. Biochem. Behav.”, 99 (2), 2011, s. 262–274, DOI: 10.1016/j.pbb.2011.05.002, PMID: 21596055, PMCID: PMC3353150.
  • J. Parker i inni, The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials, „Psychol. Res. Behav. Manag.”, 6, 2013, s. 87–99, DOI: 10.2147/PRBM.S49114, PMID: 24082796, PMCID: PMC3785407.
  • Scholten RJ, Clarke M, Hetherington J. The Cochrane Collaboration. „Eur. J. Clin. Nutr.”. 59 Suppl 1, s. S147–S149; dyskusja S195–S196, 2005. DOI: 10.1038/sj.ejcn.1602188. PMID: 16052183. 
  • Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. „Cochrane Database Syst. Rev.”, s. CD007813, 2011. DOI: 10.1002/14651858.CD007813.pub2. PMID: 21678370. 
  • Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, Vohra S. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. „Cochrane Database Syst. Rev.”. 2, s. CD009996, 2016. DOI: 10.1002/14651858.CD009996.pub2. PMID: 26844979. 
  • Pringsheim T, Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. „Cochrane Database Syst. Rev.”, s. CD007990, 2011. DOI: 10.1002/14651858.CD007990.pub2. PMID: 21491404. 
  • Spencer RC, Devilbiss DM, Berridge CW. The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex. „Biol. Psychiatry”. 77 (11), s. 940–950, June 2015. DOI: 10.1016/j.biopsych.2014.09.013. PMID: 25499957. 
  • Ilieva IP, Hook CJ, Farah MJ. Prescription Stimulants’ Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis. „J. Cogn. Neurosci.”, s. 1–21, 2015. DOI: 10.1162/jocn_a_00776. PMID: 25591060. 
  • K.S. Bagot, Y. Kaminer, Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review, „Addiction”, 109 (4), 2014, s. 547–557, DOI: 10.1111/add.12460, PMID: 24749160, PMCID: PMC4471173.
  • Devous MD, Trivedi MH, Rush AJ. Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. „J. Nucl. Med.”. 42 (4), s. 535–542, April 2001. PMID: 11337538. 
  • Wood S, Sage JR, Shuman T, Anagnostaras SG. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. „Pharmacol. Rev.”. 66 (1), s. 193–221, January 2014. DOI: 10.1124/pr.112.007054. PMID: 24344115. 
  • Teter CJ i inni, Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration, „Pharmacotherapy”, 26 (10), 2006, s. 1501–1510, DOI: 10.1592/phco.26.10.1501, PMID: 16999660, PMCID: PMC1794223.
  • L.L. Weyandt i inni, Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants, „Psychol. Res. Behav. Manag.”, 7, 2014, s. 223–249, DOI: 10.2147/PRBM.S47013, PMID: 25228824, PMCID: PMC4164338.
  • Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. „Postgrad. Med.”. 126 (5), s. 64–81, 2014. DOI: 10.3810/pgm.2014.09.2801. PMID: 25295651. 
  • J.R. Docherty, Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA), „Br. J. Pharmacol.”, 154 (3), 2008, s. 606–622, DOI: 10.1038/bjp.2008.124, PMID: 18500382, PMCID: PMC2439527.
  • Parr JW. Attention-deficit hyperactivity disorder and the athlete: new advances and understanding. „Clin. Sports Med.”. 30 (3), s. 591–610, July 2011. DOI: 10.1016/j.csm.2011.03.007. PMID: 21658550. 
  • Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R. Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing. „Sports Med.”. 43 (5), s. 301–311, May 2013. DOI: 10.1007/s40279-013-0030-4. PMID: 23456493. 
  • K.L. Parker i inni, Executive dysfunction in Parkinson’s disease and timing deficits, „Front. Integr. Neurosci.”, 7, 2013, s. 75, DOI: 10.3389/fnint.2013.00075, PMID: 24198770, PMCID: PMC3813949.
  • Rattray B, Argus C, Martin K, Northey J, Driller M. Is it time to turn our attention toward central mechanisms for post-exertional recovery strategies and performance?. „Front. Physiol.”. 6, s. 79, 2015. DOI: 10.3389/fphys.2015.00079. PMID: 25852568. PMCID: PMC4362407. 
  • Roelands B, De Pauw K, Meeusen R. Neurophysiological effects of exercise in the heat. „Scand. J. Med. Sci. Sports”. 25 Suppl 1, s. 65–78, 2015. DOI: 10.1111/sms.12350. PMID: 25943657. [dostęp 2016-03-10]. 
  • Kessler S. Drug therapy in attention-deficit hyperactivity disorder. „South. Med. J.”. 89 (1), s. 33–38, 1996. DOI: 10.1097/00007611-199601000-00005. PMID: 8545689. 
  • Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. „J. Clin. Psychiatry”. 65 (11), s. 1520–1524, 2004. DOI: 10.4088/jcp.v65n1113. PMID: 15554766. 
  • Stewart JW, Deliyannides DA, McGrath PJ. How treatable is refractory depression?. „J. Affect. Disord.”. 167, s. 148–152, 2014. DOI: 10.1016/j.jad.2014.05.047. PMID: 24972362. 
  • B. Vitiello, Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function, „Child Adolesc. Psychiatr. Clin. N. Am.”, 17 (2), 2008, s. 459–474, DOI: 10.1016/j.chc.2007.11.010, PMID: 18295156, PMCID: PMC2408826.
  • Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. „J. Investig. Allergol. Clin. Immunol.”. 16 (3), s. 148–155, 2006. PMID: 16784007. [dostęp 2015-04-29]. 
  • Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O’Duffy A, Connell FA, Ray WA. ADHD drugs and serious cardiovascular events in children and young adults. „N. Engl. J. Med.”. 365 (20), s. 1896–1904, 2011. DOI: 10.1056/NEJMoa1110212. PMID: 22043968. 
  • Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. „JAMA”. 306 (24), s. 2673–2683, 2011. DOI: 10.1001/jama.2011.1830. PMID: 22161946. PMCID: PMC3350308. 
  • E. Childs, H. de Wit, Amphetamine-induced place preference in humans, „Biological Psychiatry”, 65 (10), 2009, s. 900–904, DOI: 10.1016/j.biopsych.2008.11.016, PMID: 19111278, PMCID: PMC2693956.
  • Spiller HA, Hays HL, Aleguas A. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. „CNS Drugs”. 27 (7), s. 531–543, June 2013. DOI: 10.1007/s40263-013-0084-8. PMID: 23757186. 
  • Collaborators, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013, „The Lancet”, 385 (9963), 2015, s. 117–171, DOI: 10.1016/S0140-6736(14)61682-2, PMID: 25530442, PMCID: PMC4340604.
  • Nechifor M. Magnesium in drug dependences. „Magnes. Res.”. 21 (1), s. 5–15, March 2008. PMID: 18557129. 
  • Ruffle JK. Molecular neurobiology of addiction: what’s all the (Δ)FosB about?. „Am. J. Drug Alcohol Abuse”. 40 (6), s. 428–437, 2014. DOI: 10.3109/00952990.2014.933840. PMID: 25083822. 
  • Eric J. Nestler, Cellular basis of memory for addiction, „Dialogues in Clinical Neuroscience”, 15 (4), 2013, s. 431–443, PMID: 24459410, PMCID: PMC3898681.
  • A.J. Robison, E.J. Nestler, Transcriptional and epigenetic mechanisms of addiction, „Nat. Rev. Neurosci.”, 12 (11), 2011, s. 623–637, DOI: 10.1038/nrn3111, PMID: 21989194, PMCID: PMC3272277.
  • C.M. Olsen, Natural rewards, neuroplasticity, and non-drug addictions, „Neuropharmacology”, 61 (7), 2011, s. 1109–1122, DOI: 10.1016/j.neuropharm.2011.03.010, PMID: 21459101, PMCID: PMC3139704.
  • W.J. Lynch i inni, Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis, „Neuroscience and Biobehavioral Reviews”, 37 (8), 2013, s. 1622–1644, DOI: 10.1016/j.neubiorev.2013.06.011, PMID: 23806439, PMCID: PMC3788047.
  • Zhou Y, Zhao M, Zhou C, Li R. Sex differences in drug addiction and response to exercise intervention: From human to animal studies. „Front. Neuroendocrinol.”, 2015. DOI: 10.1016/j.yfrne.2015.07.001. PMID: 26182835. 
  • Linke SE, Ussher M. Exercise-based treatments for substance use disorders: evidence, theory, and practicality. „Am. J. Drug Alcohol Abuse”. 41 (1), s. 7–15, 2015. DOI: 10.3109/00952990.2014.976708. PMID: 25397661. 
  • M.E. Carroll, J.R. Smethells, Sex Differences in Behavioral Dyscontrol: Role in Drug Addiction and Novel Treatments, „Frontiers in Psychiatry”, 6, 2016, s. 175, DOI: 10.3389/fpsyt.2015.00175, PMID: 26903885, PMCID: PMC4745113.
  • Perez-Mana C, Castells X, Torrens M, Capella D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. „Cochrane Database Syst. Rev.”. 9, s. CD009695, 2013. DOI: 10.1002/14651858.CD009695.pub2. PMID: 23996457. 
  • Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. „Annu. Rev. Neurosci.”. 29, s. 565–598, July 2006. DOI: 10.1146/annurev.neuro.29.051605.113009. PMID: 16776597. 
  • H. Steiner, V. Van Waes, Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants, „Progress in Neurobiology”, 100, 2013, s. 60–80, DOI: 10.1016/j.pneurobio.2012.10.001, PMID: 23085425, PMCID: PMC3525776.
  • Y. Kim i inni, Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens, „Proceedings of the National Academy of Sciences of the United States of America”, 106 (8), 2009, s. 2915–2920, DOI: 10.1073/pnas.0813179106, PMID: 19202072, PMCID: PMC2650365.
  • E.J. Nestler, Epigenetic mechanisms of drug addiction, „Neuropharmacology”, 76 Pt B, 2014, s. 259–268, DOI: 10.1016/j.neuropharm.2013.04.004, PMID: 23643695, PMCID: PMC3766384.
  • K. Blum i inni, Sex, drugs, and rock ‘n’ roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms, „J. Psychoactive Drugs”, 44 (1), 2012, s. 38–55, DOI: 10.1080/02791072.2012.662112, PMID: 22641964, PMCID: PMC4040958.
  • K.K. Pitchers i inni, Natural and drug rewards act on common neural plasticity mechanisms with ΔFosB as a key mediator, „The Journal of Neuroscience”, 33 (8), 2013, s. 3434–3442, DOI: 10.1523/JNEUROSCI.4881-12.2013, PMID: 23426671, PMCID: PMC3865508.
  • Beloate LN, Weems PW, Casey GR, Webb IC, Coolen LM. Nucleus accumbens NMDA receptor activation regulates amphetamine cross-sensitization and deltaFosB expression following sexual experience in male rats. „Neuropharmacology”. 101, s. 154–164, 2016. DOI: 10.1016/j.neuropharm.2015.09.023. PMID: 26391065. 
  • Stoops WW, Rush CR. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. „Expert Rev Clin Pharmacol”. 7 (3), s. 363–374, 2014. DOI: 10.1586/17512433.2014.909283. PMID: 24716825. 
  • A. Forray, M. Sofuoglu, Future pharmacological treatments for substance use disorders, „British Journal of Clinical Pharmacology”, 77 (2), 2014, s. 382–400, DOI: 10.1111/j.1365-2125.2012.04474.x, PMID: 23039267, PMCID: PMC4014020.
  • Jing L, Li JX. Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction. „Eur. J. Pharmacol.”. 761, s. 345–352, 2015. DOI: 10.1016/j.ejphar.2015.06.019. PMID: 26092759. 
  • Shoptaw SJ i inni, Treatment for amphetamine withdrawal, Shoptaw SJ (red.), „Cochrane Database of Systematic Reviews” (2), 2009, DOI: 10.1002/14651858.CD003021.pub2, ISSN 1465-1858, PMID: 19370579, CD003021.
  • Advokat C. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. „J. Atten. Disord.”. 11 (1), s. 8–16, 2007. DOI: 10.1177/1087054706295605. PMID: 17606768. 
  • J.F. Bowyer, J.P. Hanig, Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity, „Temperature (Austin)”, 1 (3), 2014, s. 172–182, DOI: 10.4161/23328940.2014.982049, PMID: 27626044, PMCID: PMC5008711.
  • Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. „Neurotox. Res.”. 1 (3), s. 181–195, February 2000. DOI: 10.1007/BF03033289. PMID: 12835101. 
  • Miyazaki I, Asanuma M. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. „Acta Med. Okayama”. 62 (3), s. 141–150, June 2008. PMID: 18596830. 
  • S.K. Krueger, D.E. Williams, Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism, „Pharmacology & Therapeutics”, 106 (3), 2005, s. 357–387, DOI: 10.1016/j.pharmthera.2005.01.001, PMID: 15922018, PMCID: PMC1828602.
  • Krause J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. „Expert Rev. Neurother.”. 8 (4), s. 611–625, 2008. DOI: 10.1586/14737175.8.4.611. PMID: 18416663. 
  • D. Sulzer, How addictive drugs disrupt presynaptic dopamine neurotransmission, „Neuron”, 69 (4), 2011, s. 628–649, DOI: 10.1016/j.neuron.2011.02.010, PMID: 21338876, PMCID: PMC3065181.
  • Scholze P, Nørregaard L, Singer EA, Freissmuth M, Gether U, Sitte HH. The role of zinc ions in reverse transport mediated by monoamine transporters. „J. Biol. Chem.”. 277 (24), s. 21505–21513, 2002. DOI: 10.1074/jbc.M112265200. PMID: 11940571. 
  • Scassellati C, Bonvicini C, Faraone SV, Gennarelli M. Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. „J. Am. Acad. Child Adolesc. Psychiatry”. 51 (10), s. 1003–1019.e20, 2012. DOI: 10.1016/j.jaac.2012.08.015. PMID: 23021477. 
  • L.E. Eiden, E. Weihe, VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse, „Annals of the New York Academy of Sciences”, 1216, 2011, s. 86–98, DOI: 10.1111/j.1749-6632.2010.05906.x, PMID: 21272013, PMCID: PMC4183197.
  • B. Borowsky i inni, Trace amines: identification of a family of mammalian G protein-coupled receptors, „Proceedings of the National Academy of Sciences of the United States of America”, 98 (16), 2001, s. 8966–8971, DOI: 10.1073/pnas.151105198, PMID: 11459929, PMCID: PMC55357.
  • S.M. Underhill i inni, Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons, „Neuron”, 83 (2), 2014, s. 404–416, DOI: 10.1016/j.neuron.2014.05.043, PMID: 25033183, PMCID: PMC4159050.
  • SLC1A1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 [ Homo sapiens (human) ]. [w:] NCBI Gene [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2014-11-11].
  • H.J. Zhu i inni, Interaction of organic cation transporter 3 (SLC22A3) and amphetamine, „Journal of Neurochemistry”, 114 (1), 2010, s. 142–149, DOI: 10.1111/j.1471-4159.2010.06738.x, PMID: 20402963, PMCID: PMC3775896.
  • Rytting E, Audus KL. Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. „J. Pharmacol. Exp. Ther.”. 312 (1), s. 192–198, January 2005. DOI: 10.1124/jpet.104.072363. PMID: 15316089. 
  • Inazu M, Takeda H, Matsumiya T. The role of glial monoamine transporters in the central nervous system. „Nihon Shinkei Seishin Yakurigaku Zasshi”. 23 (4), s. 171–178, 2003. PMID: 13677912. (jap.). 
  • Vicentic A, Jones DC. The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction. „J. Pharmacol. Exp. Ther.”. 320 (2), s. 499–506, February 2007. DOI: 10.1124/jpet.105.091512. PMID: 16840648. 
  • Zhang M, Han L, Xu Y. Roles of cocaine- and amphetamine-regulated transcript in the central nervous system. „Clin. Exp. Pharmacol. Physiol.”. 39 (6), s. 586–592, June 2012. DOI: 10.1111/j.1440-1681.2011.05642.x. PMID: 22077697. 
  • G. Rogge i inni, CART peptides: regulators of body weight, reward and other functions, „Nat. Rev. Neurosci.”, 9 (10), 2008, s. 747–758, DOI: 10.1038/nrn2493, PMID: 18802445, PMCID: PMC4418456.
  • Y. Lin, R.A. Hall, M.J. Kuhar, CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6–38 as a CART receptor antagonist, „Neuropeptides”, 45 (5), 2011, s. 351–358, DOI: 10.1016/j.npep.2011.07.006, PMID: 21855138, PMCID: PMC3170513.
  • Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O’Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. „NIDA Res. Monogr.”. 178, s. 440–466, 1998. PMID: 9686407. 
  • S.J. Finnema i inni, Application of cross-species PET imaging to assess neurotransmitter release in brain, „Psychopharmacology (Berl.)”, 232 (21–22), 2015, s. 4129–4157, DOI: 10.1007/s00213-015-3938-6, PMID: 25921033, PMCID: PMC4600473.
  • G.E. Loseth, D.M. Ellingsen, S. Leknes, State-dependent μ-opioid modulation of social motivation, „Front. Behav. Neurosci.”, 8, 2014, s. 1–15, DOI: 10.3389/fnbeh.2014.00430, PMID: 25565999, PMCID: PMC4264475.
  • Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA. Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. „Biol. Psychiatry”. 72 (5), s. 371–377, 2012. DOI: 10.1016/j.biopsych.2012.01.027. PMID: 22386378. 
  • Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L, Brasic J, Wand GS. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. „Neuropsychopharmacology”. 30 (4), s. 821–832, 2005. DOI: 10.1038/sj.npp.1300667. PMID: 15702139. 
  • A.H. Lewin, G.M. Miller, B. Gilmour, Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class, „Bioorganic & Medicinal Chemistry”, 19 (23), 2011, s. 7044–7048, DOI: 10.1016/j.bmc.2011.10.007, PMID: 22037049, PMCID: PMC3236098.
  • J.J. Maguire i inni, International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature, „Pharmacological Reviews”, 61 (1), 2009, s. 1–8, DOI: 10.1124/pr.109.001107, PMID: 19325074, PMCID: PMC2830119.
  • R.A. Vaughan, J.D. Foster, Mechanisms of dopamine transporter regulation in normal and disease states, „Trends Pharmacol. Sci.”, 34 (9), 2013, s. 489–496, DOI: 10.1016/j.tips.2013.07.005, PMID: 23968642, PMCID: PMC3831354.
  • A. Ledonne i inni, Electrophysiological effects of trace amines on mesencephalic dopaminergic neurons, „Front. Syst. Neurosci.”, 5, 2011, s. 56, DOI: 10.3389/fnsys.2011.00056, PMID: 21772817, PMCID: PMC3131148.
  • F.G. Revel i inni, TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity, „Proceedings of the National Academy of Sciences of the United States of America”, 108 (20), 2011, s. 8485–8490, DOI: 10.1073/pnas.1103029108, PMID: 21525407, PMCID: PMC3101002.
  • Taylor KB. Dopamine-beta-hydroxylase. Stereochemical course of the reaction. „J. Biol. Chem.”. 249 (2), s. 454–458, 1974. PMID: 4809526. [dostęp 2014-11-06]. 
  • Horwitz D, Alexander RW, Lovenberg W, Keiser HR. Human serum dopamine-β-hydroxylase. Relationship to hypertension and sympathetic activity. „Circ. Res.”. 32 (5), s. 594–599, 1973. DOI: 10.1161/01.RES.32.5.594. PMID: 4713201. 
  • Cashman JR, Xiong YN, Xu L, Janowsky A. N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): role in bioactivation and detoxication. „J. Pharmacol. Exp. Ther.”. 288 (3), s. 1251–1260, 1999. PMID: 10027866. 
  • Santagati NA, Ferrara G, Marrazzo A, Ronsisvalle G. Simultaneous determination of amphetamine and one of its metabolites by HPLC with electrochemical detection. „J. Pharm. Biomed. Anal.”. 30 (2), s. 247–255, September 2002. DOI: 10.1016/S0731-7085(02)00330-8. PMID: 12191709. 
  • Lindemann L, Hoener MC. A renaissance in trace amines inspired by a novel GPCR family. „Trends Pharmacol. Sci.”. 26 (5), s. 274–281, May 2005. DOI: 10.1016/j.tips.2005.03.007. PMID: 15860375. 
  • Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. „Clin. Toxicol. (Phila.)”. 48 (7), s. 675–694, August 2010. DOI: 10.3109/15563650.2010.516752. ISSN 1556-3650. PMID: 20849327. 
  • Lillsunde P, Korte T. Determination of ring- and N-substituted amphetamines as heptafluorobutyryl derivatives. „Forensic Sci. Int.”. 49 (2), s. 205–213, 1991. DOI: 10.1016/0379-0738(91)90081-s. PMID: 1855720. 
  • Patrick TM, McBee ET, Hass HB. Synthesis of arylpropylamines; from allyl chloride. „J. Am. Chem. Soc.”. 68, s. 1009–1011, 1946. DOI: 10.1021/ja01210a032. PMID: 20985610. 
  • Ritter JJ, Kalish J. A new reaction of nitriles; synthesis of t-carbinamines. „J. Am. Chem. Soc.”. 70 (12), s. 4048–4050, 1948. DOI: 10.1021/ja01192a023. PMID: 18105933. 
  • Collins M, Salouros H, Cawley AT, Robertson J, Heagney AC, Arenas-Queralt A. δ13C and δ2H isotope ratios in amphetamine synthesized from benzaldehyde and nitroethane. „Rapid Commun. Mass Spectrom.”. 24 (11), s. 1653–1658, June 2010. DOI: 10.1002/rcm.4563. PMID: 20486262. 
  • Kraemer T, Maurer HH. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. „J. Chromatogr. B Biomed. Sci. Appl.”. 713 (1), s. 163–187, August 1998. DOI: 10.1016/S0378-4347(97)00515-X. PMID: 9700558. 
  • Kraemer T, Paul LD. Bioanalytical procedures for determination of drugs of abuse in blood. „Anal. Bioanal. Chem.”. 388 (7), s. 1415–1435, August 2007. DOI: 10.1007/s00216-007-1271-6. PMID: 17468860. 
  • Goldberger BA, Cone EJ. Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry. „J. Chromatogr. A.”. 674 (1–2), s. 73–86, 1994. DOI: 10.1016/0021-9673(94)85218-9. PMID: 8075776. 
  • Paul BD, Jemionek J, Lesser D, Jacobs A, Searles DA. Enantiomeric separation and quantitation of (±)-amphetamine (±)-methamphetamine (±)-MDA (±)-MDMA, and (±)-MDEA in urine specimens by GC-EI-MS after derivatization with (R)-(–)- or (S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (MTPA). „J. Anal. Toxicol.”. 28 (6), s. 449–455, September 2004. DOI: 10.1093/jat/28.6.449. PMID: 15516295. 
  • Verstraete AG, Heyden FV. Comparison of the sensitivity and specificity of six immunoassays for the detection of amphetamines in urine. „J. Anal. Toxicol.”. 29 (5), s. 359–364, 2005. DOI: 10.1093/jat/29.5.359. PMID: 16105261. 
  • Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. „Drug Metab. Rev.”. 32 (1), s. 15–44, February 2000. DOI: 10.1081/DMR-100100562. PMID: 10711406. 
  • Cody JT. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. „J. Occup. Environ. Med.”. 44 (5), s. 435–450, May 2002. DOI: 10.1097/00043764-200205000-00012. PMID: 12024689. 
  • David Sulzer i inni, Mechanisms of neurotransmitter release by amphetamines: a review, „Progress in Neurobiology”, 75 (6), 2005, s. 406–433, DOI: 10.1016/j.pneurobio.2005.04.003, PMID: 15955613.
  • Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. „Prog. Neurobiol.”. 75 (6), s. 406–433, 2005. DOI: 10.1016/j.pneurobio.2005.04.003. PMID: 15955613. 
  • W.R. Bett, Benzedrine sulphate in clinical medicine; a survey of the literature, „Postgraduate Medical Journal”, 22, 1946, s. 205–218, DOI: 10.1136/pgmj.22.250.205, PMID: 20997404, PMCID: PMC2478360.
  • Rasmussen N. Medical science and the military: the Allies’ use of amphetamine during World War II. „J. Interdiscip. Hist.”. 42 (2), s. 205–233, August 2011. DOI: 10.1162/JINH_a_00212. PMID: 22073434. 
  • Defalque RJ, Wright AJ. Methamphetamine for Hitler’s Germany: 1937 to 1945. „Bull. Anesth. Hist.”. 29 (2), s. 21–24, 32, April 2011. DOI: 10.1016/s1522-8649(11)50016-2. PMID: 22849208. 

pubchem.ncbi.nlm.nih.gov

  • Amphetamine. [w:] PubChem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information, 2015-04-11. [dostęp 2015-04-17].
  • Amphetamine. [w:] PubChem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2013-10-13].
  • Amphetamine. [w:] Pubchem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2013-10-12].
  • p-Hydroxyamphetamine. [w:] PubChem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2013-10-15].
  • p-Hydroxynorephedrine. [w:] PubChem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2013-10-15].
  • Phenylpropanolamine. [w:] PubChem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2013-10-15].
  • Amphetamine. [w:] PubChem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2013-10-13].
  • Amphetamine Hydrochloride. [w:] Pubchem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2013-11-08].
  • Amphetamine Phosphate. [w:] Pubchem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2013-11-08].
  • Levomethamphetamine. [w:] Pubchem Compound [on-line]. United States National Library of Medicine – National Center for Biotechnology Information. [dostęp 2014-01-02].

toxnet.nlm.nih.gov

  • Amphetamine. [w:] Hazardous Substances Data Bank [on-line]. United States National Library of Medicine – Toxicology Data Network. [dostęp 2014-02-26].
  • Amphetamine. [w:] United States National Library of Medicine – Toxicology Data Network [on-line]. Hazardous Substances Data Bank. [dostęp 2014-01-05].

nlm.nih.gov

  • Amphetamine. [w:] Medical Subject Headings [on-line]. United States National Library of Medicine. [dostęp 2013-12-16].

nwafs.org

overheid.nl

wetten.overheid.nl

  • Opiumwet. Government of the Netherlands. [dostęp 2015-04-03].

sigmaaldrich.com

t3db.ca

  • Amphetamine. [w:] T3DB [on-line]. University of Alberta. [dostęp 2015-02-24].

trispharma.com

un.org

treaties.un.org

univ-paris5.fr

genatlas.medecine.univ-paris5.fr

  • mct: TAAR1. [w:] GenAtlas [on-line]. University of Paris, 2012-01-28. [dostęp 2014-05-29].

unodc.org

untruth.org

web.archive.org

webmd.com

who.int

apps.who.int

wiley.com

onlinelibrary.wiley.com

wordsareimportant.com

worldcat.org